Research progress on bioenergy metabolic mechanism of cancer

Progress in Biochemistry and Biophysics

Volumn 38, Issue 7, 2011, Pages 585-592

  Luo, Xiang Jian ^a   Cao, Ya ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Energy metabolism; Hypoxia induced factor; P53; Warburg effect

Indexed keywords

EID: 80053977468     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2010.00611     Document Type: Review

References (45)

1. Vander Heiden M G, Cantley L C, Thompson C B. Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 2009, 324(5930): 1029-1033
2. Hanahan D, Weinberg R A. The hallmarks of cancer. Cell, 2000, 100(1): 57-70 (Pubitemid 30046295)
3. DeBerardinis R J. Is cancer a disease of abnormal cellular metabolism?. New angles on an old idea. Genet Med, 2008, 10(11): 767-777
4. Warburg O. On respiratory impairment in cancer cells. Science, 1956, 124(3215): 269-270
5. Mayevsky A. Mitochondrial function and energy metabolism in cancer cells: past overview and future perspectives, Mitochondrion, 2009, 9(3): 165-179
6. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell, 2008, 13(6): 472-482 (Pubitemid 351766797)
7. Hsu P P, Sabatini D M. Cancer cell metabolism: Warburg and beyond. Cell, 2008,134(5): 703-707
8. Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr, 2007, 39(3): 223-229 (Pubitemid 47619374)
9. Kaelin W G, Ratcliffe Jr P J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell, 2008, 30(4): 393-402 (Pubitemid 351681994)
10. Semenza G L. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev, 2010, 20(1): 51-56
11. Carbia-Nagashima A, Gerez J, Perez-Castro C, et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1 alpha during hypoxia. Cell, 2007, 131(2): 309-323 (Pubitemid 47592916)
12. Cheng J, Kang X, Zhang S, et al. SUMO-specific protease 1 is essential for stabilization of HIF1 alpha during hypoxia. Cell, 2007, 131(3): 584-595 (Pubitemid 350007694)
13. Annibaldi A, Widmann C. Glucose metabolism in cancer cells. Curr Opin Clin Nutr Metab Care, 2010, 13(4): 466-470
14. Macheda M L, Rogers S, Best J D, Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol, 2005, 202(3): 654-662 (Pubitemid 40175840)
15. Kim J W, Tchemyshyov I, Semenza G L, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab, 2006, 3(3): 177-185
16. Kim J W, Gao P, Liu Y C, et al. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol, 2007, 27(21): 7381-7393 (Pubitemid 350033646)
17. Zhang H, Bosch-Marce M, Shimoda L A, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem, 2008, 283(16): 10892-10903
18. Manning B D, Cantley L C. AKT/PKB signaling: navigating downstream. Cell, 2007, 129(7): 1261-1274 (Pubitemid 46962095)
19. Robey R B, Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol, 2009, 19(1): 25-31
20. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science, 2009, 325(5947): 1555-1559
21. Shackelford D B, Vasquez D S, Corbeil J, et al. mTOR and HIF-1 alpha-mediated tumor metabolism in an LKBl mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci USA, 2009, 106(27): 11137-11142
22. Ma W, Sung H J, Park J Y, et al. A pivotal role for p53: balancing aerobic respiration and glycolysis. J Bioenerg Biomembr, 2007, 39(3): 243-246 (Pubitemid 47619376)
23. Matoba S, Kang J G, Patino W D, et al. p53 regulates mitochondrial respiration. Science, 2006, 312(5780): 1650-1653 (Pubitemid 43902663)
24. Assaily W, Benchimol S. Differential utilization of two ATPgenerating pathways is regulated by p53. Cancer Cell, 2006, 10(1): 4-6
25. Jones R G, Plas D R, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell, 2005, 18(3): 283-293 (Pubitemid 41350534)
26. Bensaad K, Tsuruta A, Selak M A, et al. TIGAR, a p.m. regulator of glycolysis and apoptosis. Cell, 2006, 126(1): 107-120 (Pubitemid 44040989)
27. Kawauchi K, Araki K, Tobiume K, et al. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol, 2008, 10(5): 611-618 (Pubitemid 351627381)
28. Hewitson K S, Lienard B M, McDonough M A, et al. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem, 2007, 282(5): 3293-3301 (Pubitemid 47084322)
29. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDHl dominantly inhibit IDHl catalytic activity and induce HIF-1 alpha. Science, 2009, 324(5924): 261-265
30. Sonveaux P, Vegran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest, 2008, 118(12): 3930-3942
31. Fukumura D, Xu L, Chen Y, et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res, 2001, 61(16): 6020-6024 (Pubitemid 32762531)
32. Wilkinson S, O'Prey J, Flicker M, et al. Hypoxia-selective macroautophagy and cell survival signaled by autocrine PDGFR activity. Genes Dev, 2009, 23(11): 1283-1288
33. Mazurek S, Boschek C B, Hugo F, et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol, 2005, 15(4): 300-308 (Pubitemid 41058775)
34. Christofk H R, Vender Heiden M G, Wu N, et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature, 2008, 452(7184): 181-186 (Pubitemid 351380242)
35. DeBerardinis R J, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA, 2007, 104(49): 19345-19350
36. Zhao G J, Lu Z Q, Yao Y M. Prog Biochem Biophys, 2010, 37(3): 252-260
37. Xiang B, Wang L, Yi M, et al. Prog Biochem Biophys, 2009, 36(6): 709-714
38. Semenza G L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 2003, 3(10): 721-732 (Pubitemid 37328811)
39. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 2007, 11(1): 37-51
40. Ristow M, Pfister M F, Yee A J, et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc Natl Acad Sci USA, 2000, 97(22): 12239-12243
41. Haridas V, Li X, Mizumachi T, et al. Avicins, a novel plant-derived metabolite lowers energy metabolism in tumor cells by targeting the outer mitochondrial membrane. Mitochondrion, 2007, 7 (3): 234-240 (Pubitemid 46395201)
42. King A, Selak M A, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene, 2006, 25(34): 4675-4682 (Pubitemid 44187617)
43. Neuzil J, Dong L F, Ramanathapuram L, et al. Vitamin E analogues as a novel group of mitocans: anti-cancer agents that act by targeting mitochondria. Mol Aspects Med, 2007, 28(5-6): 607-645 (Pubitemid 47625532)
44. Gatenby R A, Gillies R J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer, 2004, 4(11): 891-899 (Pubitemid 39472955)
45. Wang J, Liu Q, Jiang L H, et al. Chin J Magnetic Resonance, 2010, 27(3): 341-354